Studies Show Bimekizumab Benefits Patients With Hidradenitis Suppurativa
The BE HEARD I and BE HEARD II studies included more than 1000 adults with moderate to severe hidradenitis suppurativa.
The BE HEARD I and BE HEARD II studies included more than 1000 adults with moderate to severe hidradenitis suppurativa.
Patient satisfaction, outcomes, and recovery time after surgery to address hidradenitis suppurativa are identified.